Compounds for treatment of eye diseases associated with excessive vascularisation

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12208091
APP PUB NO 20230066364A1
SERIAL NO

17939109

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ACTIVE BIOTECH ABSCHEELEVAGEN 22 P O BOX 724 LUND SE-220 07

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Eriksson, Helena Torna Hällestad, SE 5 1
Kaye, Joel Netanya, IL 33 203
Törngren, Marie Genarp, SE 5 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jul 28, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 28, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 28, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00